AKT1 and cancer: Also, the genetic variations of the factors associated with the mTOR signaling pathway in cancer cells contribute to de novo resistance to the drugs targeting mTOR.286 A twist in the mTOR story has emerged with the finding that mTORC2 can directly phosphorylate AKT and stimulate a downstream signaling cascade.